To select the travellers most likely to benefit from anti-hepatitis A (HA) antibody testing, the following criteria have been proposed: (A) being born before 1945, (B) a stay over 1 year in a developing country or (C) a history of jaundice. We present a prospective study to assess the practical use of these criteria. Following a recent survey in the general population of Lausanne showing HA seroprevalence of 52.6% in the age group over 45, we included an A1 criterion (A extended to birth before 1950). Anti-HA IgG testing and a questionnaire were proposed to all travellers presenting one or more criteria. RESULTS: Out of 1187 consecutive travellers, 176 (14.8%) had one or more criteria (219 [18.5%] when A1 was used). Criteria A applied to 8....
The objective of this study was to determine the seroprevalence of hepatitis A virus (HAV) within th...
During the period from January to May 1994, the prevalence of antibodies to hepatitis A virus infect...
BACKGROUND: Knowledge about the travel-associated risks of hepatitis A and B, and the extent of pre-...
Background: Hepatitis A virus (HAV) circulation in the environment is decreasing in most industriali...
To assess the prevalence of antibodies to hepatitis A virus (anti-HAV) in future travellers, all vis...
Introduction: The Expert Committee of Travel Medicine in Switzerland claims that people who have liv...
OBJECTIVE: To assess the risk of hepatitis A in international travelers and to recommend preventive ...
Hepatitis A virus (HAV) infection is a substantial risk for travellers from low endemic countries to...
Each year ∼14 million Europeans travel to developing countries in Africa, Asia, and Latin American a...
BACKGROUND: Non-immune international travellers are at risk of acquiring hepatitis A. Although hepat...
textabstractHepatitis A virus (HAV) infection is a substantial risk for travellers from low endemic ...
Background. Hepatitis A viral infection poses a substantial risk for travelers from low‐endemic coun...
The incidence rate of hepatitis A is 3(-6)/1000 per month of stay in a developing country in unprote...
Background: Hepatitis A is endemic in many countries. Swiss guidelines recommend vaccinating patient...
WOS: 000217248600003Objective: Hepatitis A is one of the most common infectious diseases in the worl...
The objective of this study was to determine the seroprevalence of hepatitis A virus (HAV) within th...
During the period from January to May 1994, the prevalence of antibodies to hepatitis A virus infect...
BACKGROUND: Knowledge about the travel-associated risks of hepatitis A and B, and the extent of pre-...
Background: Hepatitis A virus (HAV) circulation in the environment is decreasing in most industriali...
To assess the prevalence of antibodies to hepatitis A virus (anti-HAV) in future travellers, all vis...
Introduction: The Expert Committee of Travel Medicine in Switzerland claims that people who have liv...
OBJECTIVE: To assess the risk of hepatitis A in international travelers and to recommend preventive ...
Hepatitis A virus (HAV) infection is a substantial risk for travellers from low endemic countries to...
Each year ∼14 million Europeans travel to developing countries in Africa, Asia, and Latin American a...
BACKGROUND: Non-immune international travellers are at risk of acquiring hepatitis A. Although hepat...
textabstractHepatitis A virus (HAV) infection is a substantial risk for travellers from low endemic ...
Background. Hepatitis A viral infection poses a substantial risk for travelers from low‐endemic coun...
The incidence rate of hepatitis A is 3(-6)/1000 per month of stay in a developing country in unprote...
Background: Hepatitis A is endemic in many countries. Swiss guidelines recommend vaccinating patient...
WOS: 000217248600003Objective: Hepatitis A is one of the most common infectious diseases in the worl...
The objective of this study was to determine the seroprevalence of hepatitis A virus (HAV) within th...
During the period from January to May 1994, the prevalence of antibodies to hepatitis A virus infect...
BACKGROUND: Knowledge about the travel-associated risks of hepatitis A and B, and the extent of pre-...